Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid
Abstract
:1. Introduction
2. Results and Discussion
2.1. LPA Inhibits GLUTag L-Cell GLP-1 Secretion via LPAR1/2/3
2.2. LPAR1/3 Antagonists Reverse LPA-Mediated Decreases in Mouse Serum GLP-1 Levels
2.3. DPP4 Activity in GLUTag L-Cells and Mouse Serum Is Not Altered by LPA or LPAR1/3 Antagonism
2.4. Summary and Future Directions
3. Materials and Methods
3.1. Materials
3.2. Cells
3.3. RT-qPCR and Gene Expression Analysis
3.4. GLUTag L-Cell GLP-1 Secretion Assay
3.5. Intracellular Ca2+ Assay
3.6. Intracellular cAMP Levels
3.7. Mouse Serum GLP-1 Assay
3.8. GLUTag L-Cell DPP4 Activity Assay
3.9. Mouse Serum DPP4 Activity Assay
3.10. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Baig, S.; Shabeer, M.; Parvaresh Rizi, E.; Agarwal, M.; Lee, M.H.; Ooi, D.S.Q.; Chia, C.; Aung, N.; Ng, G.; Teo, Y.; et al. Heredity of type 2 diabetes confers increased susceptibility to oxidative stress and inflammation. BMJ Open Diabetes Res. Care 2020, 8, e000945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zatterale, F.; Longo, M.; Naderi, J.; Raciti, G.A.; Desiderio, A.; Miele, C.; Beguinot, F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front. Physiol. 2019, 10, 1607. [Google Scholar] [CrossRef] [PubMed]
- Muller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [Google Scholar] [CrossRef] [PubMed]
- Gram, D.X.; Fribo, J.; Nagy, I.; Gotfredsen, C.; Charrua, A.; Hansen, J.B.; Hansen, A.J.; Szallasi, A. TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation? Med. Sci. 2019, 7, 82. [Google Scholar] [CrossRef] [Green Version]
- Ibarra Urizar, A.; Prause, M.; Wortham, M.; Sui, Y.; Thams, P.; Sander, M.; Christensen, G.L.; Billestrup, N. Beta-cell dysfunction induced by non-cytotoxic concentrations of Interleukin-1beta is associated with changes in expression of beta-cell maturity genes and associated histone modifications. Mol. Cell. Endocrinol. 2019, 496, 110524. [Google Scholar] [CrossRef]
- Lee, T.; Yun, S.; Jeong, J.H.; Jung, T.W. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol. Cell. Endocrinol. 2019, 486, 96–104. [Google Scholar] [CrossRef]
- Gagnon, J.; Sauvé, M.; Zhao, W.; Stacey, H.M.; Wiber, S.C.; Bolz, S.S.; Brubaker, P.L. Chronic Exposure to TNFα Impairs Secretion of Glucagon-Like Peptide-1. Endocrinology 2015, 156, 3950–3960. [Google Scholar] [CrossRef]
- Lehrskov-Schmidt, L.; Lehrskov-Schmidt, L.; Nielsen, S.T.; Holst, J.J.; Møller, K.; Solomon, T.P. The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics. J. Clin. Endocrinol. Metab. 2015, 100, E616–E622. [Google Scholar] [CrossRef] [Green Version]
- Zietek, T.; Rath, E. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Front. Immunol. 2016, 7, 154. [Google Scholar] [CrossRef] [Green Version]
- Sugimoto, N.; Takuwa, N.; Yoshioka, K.; Takuwa, Y. Rho-dependent, Rho kinase-independent inhibitory regulation of Rac and cell migration by LPA1 receptor in Gi-inactivated CHO cells. Exp. Cell Res. 2006, 312, 1899–1908. [Google Scholar] [CrossRef]
- Yung, Y.C.; Stoddard, N.C.; Chun, J. LPA receptor signaling: Pharmacology, physiology, and pathophysiology. J. Lipid Res. 2014, 55, 1192–1214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Michalczyk, A.; Budkowska, M.; Dolegowska, B.; Chlubek, D.; Safranow, K. Lysophosphatidic acid plasma concentrations in healthy subjects: Circadian rhythm and associations with demographic, anthropometric and biochemical parameters. Lipids Health Dis. 2017, 16, 140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Knowlden, S.; Georas, S.N. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J. Immunol. 2014, 192, 851–857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holst, J.J.; Knop, F.K.; Vilsboll, T.; Krarup, T.; Madsbad, S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011, 34 (Suppl. 2), S251–S257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. LPA receptors: Subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 157–186. [Google Scholar] [CrossRef] [Green Version]
- Dusaulcy, R.; Rancoule, C.; Gres, S.; Wanecq, E.; Colom, A.; Guigne, C.; van Meeteren, L.; Moolenaar, W.H.; Valet, P.; Saulnier-Blache, J.S. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 2011, 52, 1247–1255. [Google Scholar] [CrossRef] [Green Version]
- Zhou, Y.; Little, P.J.; Ta, H.T.; Xu, S.; Kamato, D. Lysophosphatidic acid and its receptors: Pharmacology and therapeutic potential in atherosclerosis and vascular disease. Pharmacol. Ther. 2019, 204, 107404. [Google Scholar] [CrossRef]
- Rancoule, C.; Dusaulcy, R.; Treguer, K.; Gres, S.; Guigne, C.; Quilliot, D.; Valet, P.; Saulnier-Blache, J.S. Depot-specific regulation of autotaxin with obesity in human adipose tissue. J. Physiol. Biochem. 2012, 68, 635–644. [Google Scholar] [CrossRef]
- Honda, Y.; Imajo, K.; Kobayashi, T.; Kessoku, T.; Ogawa, Y.; Tomeno, W.; Yoneda, M.; Kobayashi, N.; Saito, S.; Nakajima, A. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol. Res. 2019, 49, 1136–1146. [Google Scholar] [CrossRef]
- Lee, S.C.; Dacheux, M.A.; Norman, D.D.; Balázs, L.; Torres, R.M.; Augelli-Szafran, C.E.; Tigyi, G.J. Regulation of Tumor Immunity by Lysophosphatidic Acid. Cancers 2020, 12, 1202. [Google Scholar] [CrossRef]
- Gu, C.; Wang, F.; Zhao, Z.; Wang, H.; Cong, X.; Chen, X. Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA(2) in Macrophages. Front. Physiol. 2017, 8, 266. [Google Scholar] [CrossRef] [PubMed]
- Dohi, T.; Miyauchi, K.; Ohkawa, R.; Nakamura, K.; Kurano, M.; Kishimoto, T.; Yanagisawa, N.; Ogita, M.; Miyazaki, T.; Nishino, A.; et al. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis 2013, 229, 192–197. [Google Scholar] [CrossRef] [PubMed]
- Ley, S.H.; Schulze, M.B.; Hivert, M.F.; Meigs, J.B.; Hu, F.B. Risk Factors for Type 2 Diabetes. In Diabetes in America; Cowie, C.C., Casagrande, S.S., Menke, A., Cissell, M.A., Eberhardt, M.S., Meigs, J.B., et al., Eds.; National Institute of Diabetes and Digestive and Kidney Diseases (US): Bethesda, MD, USA, 2018. [Google Scholar]
- Lonardo, A.; Lugari, S.; Ballestri, S.; Nascimbeni, F.; Baldelli, E.; Maurantonio, M. A round trip from nonalcoholic fatty liver disease to diabetes: Molecular targets to the rescue? Acta Diabetol. 2019, 56, 385–396. [Google Scholar] [CrossRef] [PubMed]
- Ramteke, P.; Deb, A.; Shepal, V.; Bhat, M.K. Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. Cancers 2019, 11, 1402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Ouazzani, J.; Ghalem, A.; El Ouazzani, G.; Ismaili, N.; El Ouafi, N. Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. J. Saudi Heart Assoc. 2018, 30, 113–121. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.S.; Olefsky, J. Chronic tissue inflammation and metabolic disease. Genes Dev. 2021, 35, 307–328. [Google Scholar] [CrossRef] [PubMed]
- Rancoule, C.; Attane, C.; Gres, S.; Fournel, A.; Dusaulcy, R.; Bertrand, C.; Vinel, C.; Tréguer, K.; Prentki, M.; Valet, P.; et al. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 2013, 56, 1394–1402. [Google Scholar] [CrossRef] [Green Version]
- Buteau, J.; El-Assaad, W.; Rhodes, C.J.; Rosenberg, L.; Joly, E.; Prentki, M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47, 806–815. [Google Scholar]
- Li, Y.; Cao, X.; Li, L.X.; Brubaker, P.L.; Edlund, H.; Drucker, D.J. Beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005, 54, 482–491. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Hansotia, T.; Yusta, B.; Ris, F.; Halban, P.A.; Drucker, D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278, 471–478. [Google Scholar] [CrossRef] [Green Version]
- Dhanvantari, S.; Seidah, N.G.; Brubaker, P.L. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol. Endocrinol. 1996, 10, 342–355. [Google Scholar] [PubMed] [Green Version]
- Tucker, J.D.; Dhanvantari, S.; Brubaker, P.L. Proglucagon processing in islet and intestinal cell lines. Regul. Pept. 1996, 62, 29–35. [Google Scholar] [CrossRef]
- Thorens, B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 1992, 89, 8641–8645. [Google Scholar] [CrossRef] [Green Version]
- Drucker, D.J.; Philippe, J.; Mojsov, S.; Chick, W.L.; Habener, J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 1987, 84, 3434–3438. [Google Scholar] [CrossRef] [Green Version]
- Weir, G.C.; Mojsov, S.; Hendrick, G.K.; Habener, J.F. Glucagonlike peptide I (7–37) actions on endocrine pancreas. Diabetes 1989, 38, 338–342. [Google Scholar] [CrossRef] [PubMed]
- Gromada, J.; Brock, B.; Schmitz, O.; Rorsman, P. Glucagon-like peptide-1: Regulation of insulin secretion and therapeutic potential. Basic Clin. Pharmacol. Toxicol. 2004, 95, 252–262. [Google Scholar] [CrossRef]
- Arakawa, M.; Ebato, C.; Mita, T.; Hirose, T.; Kawamori, R.; Fujitani, Y.; Watada, H. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem. Biophys. Res. Commun. 2009, 390, 809–814. [Google Scholar] [CrossRef]
- Kawamori, D.; Shirakawa, J.; Liew, C.W.; Hu, J.; Morioka, T.; Duttaroy, A.; Burkey, B.; Kulkarni, R.N. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in betaIRKO mice. Diabetologia 2017, 60, 1442–1453. [Google Scholar] [CrossRef]
- Gribble, F.M.; Williams, L.; Simpson, A.K.; Reimann, F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003, 52, 1147–1154. [Google Scholar] [CrossRef] [Green Version]
- Mace, O.J.; Schindler, M.; Patel, S. The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J. Physiol. 2012, 590, 2917–2936. [Google Scholar] [CrossRef]
- Reimann, F.; Gribble, F.M. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002, 51, 2757–2763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Christensen, L.W.; Kuhre, R.E.; Janus, C.; Svendsen, B.; Holst, J.J. Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiol. Rep. 2015, 3, e12551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11, 90–94. [Google Scholar] [CrossRef] [PubMed]
- Brubaker, P.L. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991, 128, 3175–3182. [Google Scholar] [CrossRef]
- Simpson, A.K.; Ward, P.S.; Wong, K.Y.; Collord, G.J.; Habib, A.M.; Reimann, F.; Gribble, F. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 2007, 50, 2181–2189. [Google Scholar] [CrossRef] [Green Version]
- Ellingsgaard, H.; Seelig, E.; Timper, K.; Coslovsky, M.; Soederlund, L.; Lyngbaek, M.P.; Albrechtsen, N.J.W.; Schmidt-Trucksäss, A.; Hanssen, H.; Frey, W.O.; et al. GLP-1 secretion is regulated by IL-6 signalling: A randomised, placebo-controlled study. Diabetologia 2020, 63, 362–373. [Google Scholar] [CrossRef]
- Gagnon, J.; Baggio, L.L.; Drucker, D.J.; Brubaker, P.L. Ghrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes 2015, 64, 1513–1521. [Google Scholar] [CrossRef] [Green Version]
- Geraldo, L.H.M.; Spohr, T.; Amaral, R.F.D.; Fonseca, A.; Garcia, C.; Mendes, F.A.; Freitas, C.; Fabio dosSantos, M.; Lima, F.R.S. Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies. Signal Transduct. Target. Ther. 2021, 6, 45. [Google Scholar] [CrossRef]
- Lee, J.H.; Kim, D.; Oh, Y.S.; Jun, H.S. Lysophosphatidic Acid Signaling in Diabetic Nephropathy. Int. J. Mol. Sci. 2019, 20, 2850. [Google Scholar] [CrossRef] [Green Version]
- Tigyi, G.; Parrill, A.L. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 2003, 42, 498–526. [Google Scholar] [CrossRef]
- Yanagida, K.; Ishii, S. Non-Edg family LPA receptors: The cutting edge of LPA research. J. Biochem. 2011, 150, 223–232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 2008, 1781, 513–518. [Google Scholar] [CrossRef] [PubMed]
- Tigyi, G. Aiming drug discovery at lysophosphatidic acid targets. Br. J. Pharmacol. 2010, 161, 241–270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Swaney, J.S.; Chapman, C.; Correa, L.D.; Stebbins, K.J.; Broadhead, A.R.; Bain, G.; Santini, A.M.; Darlington, J.; King, C.D.; Baccei, C.S.; et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 2011, 336, 693–700. [Google Scholar] [CrossRef] [Green Version]
- Swaney, J.S.; Chapman, C.; Correa, L.D.; Stebbins, K.J.; Bundey, R.A.; Prodanovich, P.C.; Fagan, P.; Baccei, C.S.; Santini, A.M.; Hutchinson, J.H.; et al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol. 2010, 160, 1699–1713. [Google Scholar] [CrossRef] [Green Version]
- Beck, H.P.; Kohn, T.; Rubenstein, S.; Hedberg, C.; Schwandner, R.; Hasslinger, K.; Dai, K.; Li, C.; Liang, L.; Wesche, H.; et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorganic Med. Chem. Lett. 2008, 18, 1037–1041. [Google Scholar] [CrossRef]
- Vilsboll, T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan. Med. Bull. 2004, 51, 364–370. [Google Scholar]
- Chia, C.W.; Egan, J.M. Incretins in obesity and diabetes. Ann. N. Y. Acad. Sci. 2020, 1461, 104–126. [Google Scholar] [CrossRef]
- Roussel, M.; Mathieu, J.; Dalle, S. Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic beta-cells during type 2 diabetes. Horm. Mol. Biol. Clin. Investig. 2016, 26, 87–95. [Google Scholar]
- Calanna, S.; Christensen, M.; Holst, J.J.; Laferrere, B.; Gluud, L.L.; Vilsboll, T.; Knop, F.K. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: Systematic review and meta-analyses of clinical studies. Diabetologia 2013, 56, 965–972. [Google Scholar] [CrossRef] [Green Version]
- Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117, 2340–2350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dokken, B.B.; La Bonte, L.R.; Davis-Gorman, G.; Teachey, M.K.; Seaver, N.; McDonagh, P.F. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm. Metab. Res. 2011, 43, 300–305. [Google Scholar] [CrossRef] [PubMed]
- Dokken, B.B.; Piermarini, C.V.; Teachey, M.K.; Gura, M.T.; Dameff, C.J.; Heller, B.D.; Krate, J.; Asghar, A.M.; Querin, L.; Mitchell, J.L.; et al. Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: Potential antioxidant effects. Am. J. Physiol. Heart Circ. Physiol. 2013, 304, H538–H546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109, 962–965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sokos, G.G.; Nikolaidis, L.A.; Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 2006, 12, 694–699. [Google Scholar] [CrossRef] [PubMed]
- Kotsis, V.; Jordan, J.; Stabouli, S.; Antza, C.; Micic, D.; Jelakovic, B.; Schlaich, M.; Nilsson, P.M.; Kreutz, R.; Mancia, G.; et al. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: Consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. J. Hypertens. 2020, 38, 377–386. [Google Scholar] [CrossRef] [PubMed]
- Mullins, R.J.; Mustapic, M.; Chia, C.W.; Carlson, O.; Gulyani, S.; Tran, J.; Li, Y.; Mattson, M.P.; Resnick, S.; Egan, J.M.; et al. A Pilot Study of Exenatide Actions in Alzheimer’s Disease. Curr. Alzheimer Res. 2019, 16, 741–752. [Google Scholar] [CrossRef]
- Salles, G.N.; Calio, M.L.; Holscher, C.; Pacheco-Soares, C.; Porcionatto, M.; Lobo, A.O. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer’s disease. Neuropharmacology 2020, 162, 107813. [Google Scholar] [CrossRef]
- Vadini, F.; Simeone, P.G.; Boccatonda, A.; Guagnano, M.T.; Liani, R.; Tripaldi, R.; Di Castelnuovo, A.; Cipollone, F.; Consoli, A.; Santilli, F. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: A randomized, controlled study. Int. J. Obes. (Lond.) 2020, 44, 1254–1263. [Google Scholar] [CrossRef]
- Wium-Andersen, I.K.; Osler, M.; Jorgensen, M.B.; Rungby, J.; Wium-Andersen, M.K. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: A nested case-control study. Eur. J. Endocrinol. 2019, 181, 499–507. [Google Scholar] [CrossRef]
- Bradley, R.M.; Mardian, E.B.; Moes, K.A.; Duncan, R.E. Acute Fasting Induces Expression of Acylglycerophosphate Acyltransferase (AGPAT) Enzymes in Murine Liver, Heart, and Brain. Lipids 2017, 52, 457–461. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fernandes, M.F.; Tomczewski, M.V.; Duncan, R.E. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. Int. J. Mol. Sci. 2022, 23, 4163. https://doi.org/10.3390/ijms23084163
Fernandes MF, Tomczewski MV, Duncan RE. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. International Journal of Molecular Sciences. 2022; 23(8):4163. https://doi.org/10.3390/ijms23084163
Chicago/Turabian StyleFernandes, Maria F., Michelle V. Tomczewski, and Robin E. Duncan. 2022. "Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid" International Journal of Molecular Sciences 23, no. 8: 4163. https://doi.org/10.3390/ijms23084163